1. Introduction {#sec1-genes-06-01256}
===============

*Staphylococcus aureus* is an opportunistic bacterial pathogen that can cause severe infections in hospital and the community. Due to the emergence of multi-drug resistance in *S. aureus*, treatment now relies on last-line antibiotics, including daptomycin. Daptomycin is a cyclic lipopeptide antibiotic that targets the bacterial membrane for its bactericidal activity, a mechanism similar to host cationic antimicrobial peptides. Unfortunately, therapeutic failures with daptomycin for infections due to *S. aureus* have now been reported \[[@B1-genes-06-01256],[@B2-genes-06-01256]\]. The majority of these patients had deep-seated infection, such as endocarditis or osteomyelitis, and increases in minimum inhibitory concentration (MIC) of daptomycin were observed after prolonged therapy \[[@B1-genes-06-01256],[@B2-genes-06-01256]\]. It is postulated that the levels of daptomycin may have been sub-therapeutic at the site of infection. In this study, we used the term daptomycin resistance (DAP-R) (daptomycin MIC \> 1 μg/mL) instead of daptomycin non-susceptibility.

Studies thus far show that *S. aureus* acquires DAP-R via the accumulation of single nucleotide polymorphisms (SNPs) in genes related to the biogenesis of the cell membrane and cell wall, especially the multi-peptide resistance factor gene *mprF* and the essential two component regulator *walKR* (also known as *yycGF*) \[[@B3-genes-06-01256]\]. MprF is a lysyl-phosphatidylglycerol (L-PG) synthetase with two functional domains that synthesizes L-PG and facilitates L-PG translocation to the outer leaflet of the cell membrane respectively \[[@B4-genes-06-01256]\]. SNPs in *mprF* associated with DAP-R cause a gain-in-function and therefore lead to more total L-PG or more L-PG in the outer leaflet of the membrane \[[@B5-genes-06-01256],[@B6-genes-06-01256],[@B7-genes-06-01256]\]. It is hypothesized that this leads to altered membrane charge and electrorepulsion of daptomycin \[[@B7-genes-06-01256]\]. WalK is the histidine kinase that modulates its cognate transcriptional regulator, WalR, to control cell wall biosynthesis and turnover \[[@B8-genes-06-01256]\]. Importantly, the emergence of cross-resistance to daptomycin and vancomycin, another last-line antibiotic, is concerning as several vancomycin-intermediate *S. aureus* (VISA) clinical isolates are also reported to be DAP-R even without daptomycin exposure \[[@B9-genes-06-01256],[@B10-genes-06-01256]\]. This observation is correlated with a study that recreated SNPs in *walk* and *walR* that were found in VISA clinical isolates, and showed they conferred reduced susceptibility to vancomycin and daptomycin in *S. aureus* \[[@B11-genes-06-01256]\]. Therefore, novel strategies are required to reduce the chances for deep-seated *S. aureus* infections to develop DAP-R during daptomycin treatment.

The potential benefits of combining daptomycin with aminoglycosides were first observed by Debbia *et al.*, showing synergistic killing of combination therapy against *S. aureus* in time-kill assays \[[@B12-genes-06-01256]\]. Gentamicin is one of the most active aminoglycosides to treat *S. aureus* infection and has therefore been a common additional agent investigated with daptomycin ([Table S1](#genes-06-01256-s001){ref-type="supplementary-material"}) \[[@B13-genes-06-01256],[@B14-genes-06-01256],[@B15-genes-06-01256],[@B16-genes-06-01256],[@B17-genes-06-01256],[@B18-genes-06-01256],[@B19-genes-06-01256],[@B20-genes-06-01256],[@B21-genes-06-01256],[@B22-genes-06-01256],[@B23-genes-06-01256],[@B24-genes-06-01256],[@B25-genes-06-01256]\]. A simulated endocardial vegetation (SEV) model has also been used to assess the efficacy of daptomycin plus gentamicin \[[@B26-genes-06-01256]\]. The combination enhanced bactericidal activity in some SEV studies \[[@B16-genes-06-01256],[@B23-genes-06-01256]\] but was indifferent from daptomycin monotherapy in other SEV studies \[[@B22-genes-06-01256],[@B25-genes-06-01256]\]. The inconsistent results may be due to differences between bacterial strains and unknown levels of daptomycin penetrating into SEVs. It has previously been shown that \~91%--94% of daptomycin in plasma is bound to proteins, and based on peak daptomycin concentrations (98--133 μg/mL) achieved after standard dosing (6 or 8 mg/kg/day), concentrations of free daptomycin in tissues and bones are reported between 1.6 and 8 μg/mL \[[@B27-genes-06-01256],[@B28-genes-06-01256],[@B29-genes-06-01256]\]. Thus far, less is known about the efficacy of daptomycin-gentamicin combination using daptomycin concentrations likely found in deep-seated infection sites and against isolates that have genetically characterized daptomycin resistance mechanisms \[[@B15-genes-06-01256],[@B17-genes-06-01256],[@B20-genes-06-01256],[@B25-genes-06-01256]\].

In this study, we investigated the synergy between daptomycin and gentamicin using genetically characterized *S. aureus* DAP-R isolates, as well as DAP-S isolates from patients with deep-seated infections. Two of the DAP-R isolates were only exposed to daptomycin whilst the other two DAP-R isolates were only exposed to vancomycin. Given the majority of infections that fail daptomycin therapy are complicated bacteremia cases with associated deep-seated infection, we chose a clinically relevant range of daptomycin concentrations to assess for enhanced killing with gentamicin.

2. Experimental Section {#sec2-genes-06-01256}
=======================

2.1. Bacterial Strains {#sec2dot1-genes-06-01256}
----------------------

We examined eight *S. aureus* clinical isolates ([Table 1](#genes-06-01256-t001){ref-type="table"}), six of which were paired isolates from three patients. Four pre-treatment methicillin-resistant *S. aureus* (MRSA) isolates (A9719, A8819, A8796 and A6224), two VISA strains with DAP-R that emerged after vancomycin therapy (A6226 and A9639), and two DAP-R *S. aureus* isolates that emerged after daptomycin therapy (A9744 and A8817), were included \[[@B2-genes-06-01256],[@B7-genes-06-01256],[@B10-genes-06-01256],[@B30-genes-06-01256]\]. All isolates underwent whole genome sequencing as described previously \[[@B7-genes-06-01256],[@B10-genes-06-01256]\]. The genetic mutations identified by whole-genome analysis between paired DAP-R isolates and DAP-S progenitors in previous studies are shown in [Table S2](#genes-06-01256-s001){ref-type="supplementary-material"} \[[@B7-genes-06-01256],[@B10-genes-06-01256]\].

genes-06-01256-t001_Table 1

###### 

*Staphylococcus aureus* isolates used in the present study.

  Patient   Strains      Clinical Syndrome                 Multi-Locus Sequence Type   MIC (μg/mL)   References         
  --------- ------------ --------------------------------- --------------------------- ------------- ------------ ----- -------------------------------------------------
  1         A6224        Bacteremia                        5                           0.25          2            0.5   \[[@B10-genes-06-01256]\]
  A6226     2            4                                 0.5                                                          
  2         A9719        Endocarditis                      5                           0.25          2            0.5   \[[@B7-genes-06-01256]\]
  A9744     2            2                                 1                                                            
  3         A8819        Osteomyelitis, septic arthritis   105                         0.25          1            0.5   \[[@B7-genes-06-01256]\]
  A8817     2            1                                 0.5                                                          
  4         A8796        Bacteremia, osteomyelitis         105                         0.25          1            0.5   \[[@B2-genes-06-01256],[@B7-genes-06-01256]\]
  5         A9639        Bacteremia, osteomyelitis         1892                        2             4            1     \[[@B10-genes-06-01256],[@B30-genes-06-01256]\]
  Control   ATCC 29213   −                                 −                           0.25          1            0.5   −

2.2. Antibiotic Susceptibility Testing {#sec2dot2-genes-06-01256}
--------------------------------------

Daptomycin (Cubist Pharmaceuticals, Lexington, MA, USA) susceptibility testing was performed by broth macrodilution (inoculum, 5 × 10^5^ CFU/mL) using cation-adjusted Mueller-Hinton broth (Beckton Dickinson, Cockeysville, MD, USA) supplemented to contain a final calcium concentration of 50 μg/mL. Susceptibility to vancomycin and gentamicin was performed by agar dilution according to the Clinical and Laboratory Standards Institute (CLSI) \[[@B31-genes-06-01256]\]. *S. aureus* ATCC 29213 was used as a control.

2.3. Time-Kill Analyses {#sec2dot3-genes-06-01256}
-----------------------

Time-kill studies, as described previously, were performed to assess for enhanced killing \[[@B26-genes-06-01256],[@B32-genes-06-01256]\]. An inoculum of 10^6^ CFU/mL of fresh overnight cultures was used. Calcium supplemented (final concentration of 50 μg/mL), cation-adjusted Mueller-Hinton broth was used for all time-kill studies. Bacterial colony counts were performed in duplicate at baseline, 4 h and 24 h after incubation at 35 °C. Two hundred microliters were sampled from the undiluted flask at 24 h resulting in a lower limit of organism detection of 5 CFU/mL. Enhanced killing was defined as a ≥2 log~10~ decrease in CFU/mL between the combination and its most active component after 24 h. At least one of the drugs had to be present in a concentration that did not significantly affect the growth curve of the organism when used alone \[[@B32-genes-06-01256]\]. For the DAP-S isolates (A6224, A9719, A8819, and A8796), we studied daptomycin concentrations between 0.5 and 6 μg/mL (2× MIC to 20× MIC). For the DAP-R *S. aureus* isolates (A6226, A9639, A9744 and A8817), we studied daptomycin concentrations between 4 μg/mL and 16 μg/mL (2 × MIC to 8× MIC). The concentration of gentamicin in skeletal muscle and subcutaneous tissue varies depending on gentamicin concentration in serum, gender, age, the degree of peripheral arterial disease and pathological state of the tissue \[[@B33-genes-06-01256],[@B34-genes-06-01256],[@B35-genes-06-01256]\]. A range between 0.3 μg/mL and 7 μg/mL gentamicin in skeletal muscle and tissue was reported in the literature after a 3 mg/kg/day dose \[[@B33-genes-06-01256],[@B34-genes-06-01256],[@B35-genes-06-01256],[@B36-genes-06-01256]\]. To simulate a low gentamicin concentration in deep-seated infection, a gentamicin dose of 0.25 μg/mL or 0.5 μg/mL (0.5× MIC) was used in time-kill analyses.

3. Results and Discussion {#sec3-genes-06-01256}
=========================

3.1. Synergistic Bactericidal Effects of Gentamicin and Daptomycin at the Concentration Mimicking That in Tissue Compartments {#sec3dot1-genes-06-01256}
-----------------------------------------------------------------------------------------------------------------------------

Lower daptomycin levels are expected in tissue compartments other than blood due to high levels of protein binding of daptomycin and low penetration ratio into tissue compartments \[[@B27-genes-06-01256],[@B28-genes-06-01256],[@B29-genes-06-01256],[@B37-genes-06-01256],[@B38-genes-06-01256]\]. The fact that the majority of daptomycin treatment failures described thus far have been due to infections in these non-blood compartments indicates the clinical relevance of these experiments \[[@B2-genes-06-01256]\]. Of the four DAP-S isolates, three showed enhanced killing between daptomycin and gentamicin (A6224, A9719, A8796) ([Figure 1](#genes-06-01256-f001){ref-type="fig"}). Enhanced killing was most common at a daptomycin concentration of 4 μg/mL but was observed down to 1 μg/mL. Daptomycin concentration above 4 μg/mL, alone or combined with gentamicin, resulted in rapid bacterial killing whilst significant regrowth was observed for daptomycin concentrations below 1 μg/mL alone and the combination \[[@B39-genes-06-01256]\].

To assess whether the mechanism of enhanced killing was by the prevention of secondary daptomycin resistance, the MIC of daptomycin was tested on the organisms that had regrowth at 24 h. The MIC of daptomycin increased from 0.25 μg/mL to 1.0 μg/mL for A6224, and from 0.25 μg/mL to 0.5 μg/mL for the other three isolates (A9719, A8819, and A8796), suggesting that combination therapy effectively prevented the emergence of DAP-R.

![Time-kill studies of four DAP-S, methicillin-resistant *S. aureus* isolates showed enhanced killing with the combination of daptomycin and gentamicin at daptomycin concentrations between 1 μg/mL and 4 μg/mL. (**A**) A6224; (**B**) A9719; (**C**) A8819; and (**D**) A8796.](genes-06-01256-g001){#genes-06-01256-f001}

3.2. The Combination of Daptomycin and Gentamicin Effectively Eradicated Daptomycin-Exposed or Vancomycin-Exposed DAP-R S. aureus Isolates {#sec3dot2-genes-06-01256}
------------------------------------------------------------------------------------------------------------------------------------------

Limited data are available examining the efficacy of combining daptomycin and gentamicin to kill DAP-R isolates. The genetic mutations associated with the DAP-R strains used in this study are shown in [Table S2](#genes-06-01256-s001){ref-type="supplementary-material"}. The daptomycin-exposed DAP-R isolates (A8817 and A9744) contain SNPs in genes related to phospholipid biogenesis, including *mprF* and cardiolipin synthase 2 (*cls2*) \[[@B7-genes-06-01256]\]. Although electrorepulsion to DAP caused by alteration of membrane phospholipids was proposed as the mechanism behind DAP-R, more studies are required to elucidate how the alteration of membrane phospholipids leads to DAP-R \[[@B7-genes-06-01256]\]. Importantly, enhanced killing with the combination of daptomycin 4 μg/mL and gentamicin was seen for the two DAP-R isolates (A8817 and A9744) ([Figure 2](#genes-06-01256-f002){ref-type="fig"}).

![Time-kill studies of two DAP-R *S. aureus* isolates that developed after exposure to daptomycin; (**A**) A8817 and (**B**) A9744.](genes-06-01256-g002){#genes-06-01256-f002}

For the vancomycin-exposed DAP-R isolates A6226 and A9639, the synergy between daptomycin and gentamicin was also observed at a daptomycin concentration of 4 μg/mL and 8 μg/mL ([Figure 3](#genes-06-01256-f003){ref-type="fig"}). Daptomycin concentrations above 8 μg/mL led to substantial killing by daptomycin alone and with the combination. A6226 contains a mutation in *yycI*, which is predicted to be the regulatory protein for the *walKR* operon, and a SNP in *dltA*, which is in the *dlt* operon responsible for D-analylation of wall teichoic acids \[[@B10-genes-06-01256]\]. Mutations in *walK* and *walR* were shown to be associated with DAP-R and overexpression of the *dlt* operon was found in a daptomycin-exposed, DAP-R isolate, indicating that modification of the cell wall may impact daptomycin susceptibility \[[@B11-genes-06-01256],[@B40-genes-06-01256]\]. A9639 has a SNP in *vraG*, which encodes an ABC transporter permease, and a frameshift mutation in *rpsU*, which encodes ribosomal protein S21 \[[@B10-genes-06-01256]\]. VraG is involved in resistance to host cationic antimicrobial peptides and up-regulation of *vraG* was found in a daptomycin-exposed, DAP-R isolate \[[@B41-genes-06-01256],[@B42-genes-06-01256]\]. The integration of a transposon into *rpsU* was recently shown to confer DAP-R in *S. aureus* \[[@B43-genes-06-01256]\]. Although the genetic mechanisms associated with these DAP-R isolates were diverse, enhanced killing with daptomycin combined with gentamicin was maintained across a range of phenotypes, including DAP-R isolates that had emerged after either vancomycin (VISA phenotype) or daptomycin exposure.

![Time-kill studies of two DAP-R *S. aureus* isolates that were exposed to vancomycin only; (**A**) A6226 and (**B**) A9639.](genes-06-01256-g003){#genes-06-01256-f003}

3.3. Lower Bactericidal Rates of Daptomycin and Gentamicin against Vancomycin-Exposed DAP-R Isolates Compared to the Rates against Daptomycin-Exposed DAP-R Isolates {#sec3dot3-genes-06-01256}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

We noticed that the degree of bacterial killing at 4 h was significantly lower for DAP-R isolates that had been exposed to vancomycin (VISA isolates A6226 and A9639) compared with DAP-R isolates exposed to daptomycin (A8817 and A9744), with a mean reduction in CFU/mL from baseline of 0.91 CFU/mL and 2.08 CFU/mL, respectively (*p* = 0.049, Kendall's rank correlation coefficient, STATA, version 7.0, College Station, TX, USA). This may relate to changes in the cell wall with VISA isolates interfering with daptomycin activity, or to cellular changes associated with this phenotype that confer tolerance to antimicrobials \[[@B9-genes-06-01256]\]. The difference in the rate of bactericidal activity also suggests that the mechanism of DAP-R between these two groups of organisms are likely different.

In contrast to previous studies, we have assessed bactericidal interactions between daptomycin and gentamicin against both DAP-S and DAP-R *S. aureus* isolates using a range of daptomycin concentrations that are likely present in deep-seated infection sites with current dosing \[[@B14-genes-06-01256],[@B15-genes-06-01256],[@B16-genes-06-01256],[@B17-genes-06-01256],[@B18-genes-06-01256],[@B19-genes-06-01256],[@B20-genes-06-01256],[@B21-genes-06-01256],[@B22-genes-06-01256],[@B23-genes-06-01256],[@B24-genes-06-01256],[@B25-genes-06-01256],[@B27-genes-06-01256],[@B28-genes-06-01256],[@B29-genes-06-01256],[@B37-genes-06-01256],[@B38-genes-06-01256]\]. We observed, as described by previous investigators, that at higher daptomycin concentrations (\>4 μg/mL for susceptible isolates and \>8 μg/mL for resistant isolates), rapid killing occurs, with minimal benefit of adding gentamicin \[[@B16-genes-06-01256],[@B24-genes-06-01256],[@B44-genes-06-01256]\]. However, when lower concentrations are used to a point, the addition of gentamicin has significant benefit, often showing equivalent or greater activity than a higher dose of daptomycin alone. Thus, for *S. aureus* bacteremia that is complicated by seeding to other sites, the addition of gentamicin may be of benefit. This needs to be outweighed by the potential nephro- and ototoxicity of aminoglycosides.

Our results also indicate that the addition of gentamicin may be beneficial if daptomycin is used after vancomycin failure to prevent the development of DAP-R. Daptomycin has been approved for the treatment of *S. aureus* bacteremia and right-sided infective endocarditis \[[@B1-genes-06-01256]\]. To optimize the use of daptomycin in this setting, especially in those with complicated bacteremia who are at greatest risk for therapeutic failure, further studies are required to assess the clinical significance and generalisability of the observed concentration-dependent interaction between daptomycin and gentamicin.

4. Conclusions {#sec4-genes-06-01256}
==============

The combination of gentamicin with daptomycin at concentrations likely present in deep-seated infection sites effectively eradicated *S. aureus* clinical isolates, including DAP-R isolates previously exposed to daptomycin or vancomycin. Combination therapy may provide the synergy required to prevent emergence of resistance in deep-seated, complicated infections, where daptomycin levels are below peak serum concentrations.

We acknowledge George M. Eliopoulos and the late Robert C. Moellering, Jr. for their contributions in reviewing the manuscript. Anton Y. Peleg was funded by an Australian National Health and Medical Research Council R.D. Wright Biomedical Fellowship (APP1047916) and Project Grant (APP1047918).

###### 

Click here for additional data file.

Anton Y. Peleg conceived the study. Jhih-Hang Jiang and Anton Y. Peleg performed the experiments and wrote the manuscript. Jhih-Hang Jiang prepared the figures.

The authors declare no conflicts of interest.
